TABLE 8.
Cell type, inhibitor, or DNA | No. of foci in:
|
||||||||
---|---|---|---|---|---|---|---|---|---|
Expt 1 | Expt 2 | Expt 3 | Expt 4 | ||||||
NIH 3T3 | |||||||||
SB203580 (μM) | 0 | 1 | |||||||
Transfected DNA | |||||||||
None | 0 | 0 | |||||||
pcDNA3.1 | 0 | 0 | |||||||
v-mos | 100 | 104 | |||||||
pCMV3ΔGP | 24 | 68 | |||||||
RK3E | |||||||||
SB203580 (μM) | 0 | 10 | 20 | 0 | 5 | ||||
SB202190 (μM) | 0 | 5 | |||||||
Transfected DNA | |||||||||
None | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
pcDNA3.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
v-mos | 168 | 180 | 200 | 1676 | 1432 | ||||
H-ras | 0 | 0 | 28 | ||||||
pCMV3ΔGP | 56 | 2100 | 2844 | 76 | 1896 | 324 | 4232 |
The effects of p38 MAPK inhibitors on transformation of NIH 3T3 (experiment 1) and RK3E cells (experiments 2 to 4) were tested. All assays were conducted in 6-cm dishes with 5 μg of transfected DNA. Foci were scored at 11 to 14 days posttransfection. These foci could be scored earlier due to the enhancement of transformation.